These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9734938)

  • 1. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
    Cohen J; Carlet J
    Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot clinical trial of an anti-TNF alpha monoclonal antibody for the treatment of septic shock.
    Boillot A; Capellier G; Racadot E; Wijdenes J; Herve P; Barale F
    Clin Intensive Care; 1995; 6(2):52-6. PubMed ID: 10150799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
    Jacobs S; Price Evans DA; Tariq M; Al Omar NF
    Crit Care Med; 2003 Jul; 31(7):1938-46. PubMed ID: 12847386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological status of septic and trauma patients. I. High tumor necrosis factor alpha serum levels in septic and trauma patients are not responsible for increased mortality; a prognostic value of serum interleukin 6.
    Adamik B; Zimecki M; Właszczyk A; Kübler A
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):169-75. PubMed ID: 9597083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody.
    Hinshaw LB; Emerson TE; Taylor FB; Chang AC; Duerr M; Peer GT; Flournoy DJ; White GL; Kosanke SD; Murray CK
    J Trauma; 1992 Oct; 33(4):568-73. PubMed ID: 1433404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
    Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
    Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
    Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
    Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.
    Opal SM; Cross AS; Sadoff JC; Collins HH; Kelly NM; Victor GH; Palardy JE; Bodmer MW
    J Clin Invest; 1991 Sep; 88(3):885-90. PubMed ID: 1885775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of septic shock with antibodies to tumour necrosis factor.
    Cohen J; Exley AR
    Schweiz Med Wochenschr; 1993 Mar; 123(11):492-6. PubMed ID: 8475356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study.
    Zeni F; Pain P; Vindimian M; Gay JP; Gery P; Bertrand M; Page Y; Page D; Vermesch R; Bertrand JC
    Crit Care Med; 1996 Feb; 24(2):207-14. PubMed ID: 8605790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis.
    Lv S; Han M; Yi R; Kwon S; Dai C; Wang R
    Int J Clin Pract; 2014 Apr; 68(4):520-8. PubMed ID: 24548627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
    Boerma EC; Koopmans M; Konijn A; Kaiferova K; Bakker AJ; van Roon EN; Buter H; Bruins N; Egbers PH; Gerritsen RT; Koetsier PM; Kingma WP; Kuiper MA; Ince C
    Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.